Toshihiro Koyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshihiro Koyama has a total of 268 co-authors. Here are the top co-authors by number of shared publications:
- Yoshito Zamami
Department of Pharmacy, Okayama University Hospital, Okayama, Japan
36 shared publications Yoshito Zamami
Department of Pharmacy, Okayama University Hospital, Okayama 7008558, Japan
27 shared publications- Hirofumi Hamano
Department of Pharmacy, Okayama University Hospital, Okayama, Japan
26 shared publications - Yoshihisa Kitamura
Department of pharmacotherapy, School of Pharmacy, Shujitsu University, Okayama, Japan
26 shared publications - Hideharu Hagiya
Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
25 shared publications - Caiyang Fang
Okayama University 1 Okayama
24 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7476
Burden of Five Musculoskeletal Disorders in ASEAN Countries, 1990–2023: A Global Burden of Disease Study 2023 Analysis
Background/Objectives: Five musculoskeletal disorders (MSDs), including gout, low back pain, neck pain, osteoarthritis, and rheumatoid arthritis represent a growing public health burden; however, evidence from the Association of Southeast Asian Nations (ASEAN) remains limited. This study aimed to assess the burden of these five MSDs across ten ASEAN countries. Methods: Using data from the Global Burden of Disease Study 2023, we estimated the burden using prevalence and disability-adjusted life years (DALYs). National trends from 1990 to 2023 were assessed using average annual percent change (AAPC). Results: From 1990 to 2023, the absolute numbers of prevalent cases and absolute numbers of DALYs increased, with low back pain and osteoarthritis accounting for large shares across the ten countries. Country-level patterns differed between absolute numbers and age-standardised rates of the five MSDs. In 2023, age-specific absolute numbers of prevalent cases and absolute numbers of DALYs increased with age before declining in older age groups, with peak ages varying across the five MSDs. Across the five MSDs, age-standardised prevalence rates were generally higher among females, while gout showed higher rates among males. Age-standardised prevalence rates showed generally modest positive AAPCs for osteoarthritis, rheumatoid arthritis, and gout, whereas low back pain and neck pain showed decreasing trends in most countries. Conclusions: The increasing burden in absolute numbers of the five MSDs across the ten ASEAN countries, together with persistent sex disparities, differences in age-specific patterns, variations in age-standardised trends, and considerable country-level heterogeneity, highlights the need for continued attention to the burden of the five MSDs in the region.
- 25 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7476
Open AccessBurden of Five Musculoskeletal Disorders in ASEAN Countries, 1990–2023: A Global Burden of Disease Study 2023 Analysis
Background/Objectives: Five musculoskeletal disorders (MSDs), including gout, low back pain, neck pain, osteoarthritis, and rheumatoid arthritis represent a growing public health burden; however, evidence from the Association of Southeast Asian Nations (ASEAN) remains limited. This study aimed to assess the burden of these five MSDs across ten ASEAN countries. Methods: Using data from the Global Burden of Disease Study 2023, we estimated the burden using prevalence and disability-adjusted life years (DALYs). National trends from 1990 to 2023 were assessed using average annual percent change (AAPC). Results: From 1990 to 2023, the absolute numbers of prevalent cases and absolute numbers of DALYs increased, with low back pain and osteoarthritis accounting for large shares across the ten countries. Country-level patterns differed between absolute numbers and age-standardised rates of the five MSDs. In 2023, age-specific absolute numbers of prevalent cases and absolute numbers of DALYs increased with age before declining in older age groups, with peak ages varying across the five MSDs. Across the five MSDs, age-standardised prevalence rates were generally higher among females, while gout showed higher rates among males. Age-standardised prevalence rates showed generally modest positive AAPCs for osteoarthritis, rheumatoid arthritis, and gout, whereas low back pain and neck pain showed decreasing trends in most countries. Conclusions: The increasing burden in absolute numbers of the five MSDs across the ten ASEAN countries, together with persistent sex disparities, differences in age-specific patterns, variations in age-standardised trends, and considerable country-level heterogeneity, highlights the need for continued attention to the burden of the five MSDs in the region.
- Open Access
- 27 August 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (10) , 103349
Global trends in leprosy-related incidence and disease burden from 1990 to 2021: A secondary analysis of the global burden of disease study
- 27 August 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (10) , 103349
Open AccessGlobal trends in leprosy-related incidence and disease burden from 1990 to 2021: A secondary analysis of the global burden of disease study
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Gating strategy for T follicular helper (TFH) cells in flow cytometry analysis
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Gating strategy for T follicular helper (TFH) cells in flow cytometry analysis
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Multicolor immunohistochemistry images for CD4, CD8, and FOXP3 in FL and DLBCL
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Multicolor immunohistochemistry images for CD4, CD8, and FOXP3 in FL and DLBCL
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Definition of radiotherapy in this study
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Definition of radiotherapy in this study
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Immunohistochemistry for CD40, IL-4R, and IL-21R of cases 1 and 2
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Immunohistochemistry for CD40, IL-4R, and IL-21R of cases 1 and 2
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Patient selection flowchart in the VigiBase database
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Patient selection flowchart in the VigiBase database